about
Characterization of hnRNP K protein-RNA interactions.Prognostic value of microRNA expression in operable non-small cell lung cancer patientsLandscape of the hnRNP K protein-protein interactomeThe fold recognition of CP2 transcription factors gives new insights into the function and evolution of tumor suppressor protein p53.Heterogeneous nuclear ribonucleoprotein K protein associates with multiple mitochondrial transcripts within the organelle.Ligand.Info small-molecule Meta-Database.Epstein-Barr virus late gene transcription depends on the assembly of a virus-specific preinitiation complex.KMAD: knowledge-based multiple sequence alignment for intrinsically disordered proteins.Mediastinal paragangliomas related to SDHx gene mutations.Integrating genomics, proteomics and bioinformatics in translational studies of molecular medicine.Mapping the substrate binding site of phenylacetone monooxygenase from Thermobifida fusca by mutational analysis.MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.Detecting reliable non interacting proteins (NIPs) significantly enhancing the computational prediction of protein-protein interactions using machine learning methods.Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on GastrointesGROWTH RATE OF PARAGANGLIOMAS RELATED TO GERMLINE MUTATIONS OF THE SDHX GENES.Does the addition of oxaliplatin to preoperative chemoradiation benefit cT4 or fixed cT3 rectal cancer treatment? A subgroup analysis from a prospective study.Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: long-term results of a phase II study.Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study.Watch and wait policy after preoperative radiotherapy for rectal cancer; management of residual lesions that appear clinically benign.Three clinical variants of gastroesophageal reflux disease form two distinct gene expression signatures.Hematological Toxicity of Hypofractionated Radiotherapy: A Review of the Available EvidencePlant nitric oxide synthase: a never-ending story?ShapeGTB: the role of local DNA shape in prioritization of functional variants in human promoters with machine learningAvelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trialAvelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trialARLTS1 Trp149Stop Mutation and the Risk of Ovarian CancerIdentification of a common risk haplotype for diabetic nephropathy at the protein kinase C-beta1 (PRKCB1) gene locusLigProf: a simple tool for in silico prediction of ligand-binding sitesMolecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomicsCooperative binding of the hnRNP K three KH domains to mRNA targetsPalliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II studyNeoadjuvant treatment for unresectable rectal cancer: an interim analysis of a multicentre randomized studyThe feasibility of short-course radiotherapy in a watch-and-wait policy for rectal cancerRectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upRectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upPhase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300Impact of pelvic bone marrow irradiation on the hematological toxicity of subsequent chemotherapy in rectal cancerHigh-density Peptide Arrays Help to Identify Linear Immunogenic B-cell Epitopes in Individuals Naturally Exposed to Malaria InfectionAssociation between Preoperative Pelvic Irradiation and Toxicity of Subsequent Chemotherapy in Rectal Cancer.
P50
Q27929885-D1CD2781-BC5B-48F9-9235-6C6ACF97F5A2Q28396343-F3132BAD-F989-494F-B170-C325760CB66AQ28572494-3D687973-FD0A-4BFA-B68F-B5DCBF2055E6Q30372030-3C678235-3F58-438A-A104-03E0EF7D7D30Q30777871-7E175C18-BC28-4CA9-9C6E-68620E98EC85Q33209546-ECC9AD11-F818-4882-A0BD-043420A949D3Q34593751-42DF9D52-977F-402A-8F60-563C49D0A795Q36716505-36B35A7A-0AC1-408C-8AAA-769D30E16BBFQ37352164-DEDBD818-08A4-4EA5-BC41-477BBD1A2319Q37592256-A8AAD45D-F45D-43D5-897F-43DAB3BFD11EQ38282592-2A442276-33F3-446B-BAD2-80FF3B1BBCDFQ39161150-615E6850-78B7-4925-A24A-B94AAB3284D0Q40135840-7EFC4772-1C6F-4513-99DF-FD9A2C91C52FQ48501675-D4645A73-241D-4D4B-B772-789BA2049B40Q50077151-843096C3-74E4-4AE9-B15E-28D57D8319EEQ51012320-82FE9EFE-4BA0-4417-BD1B-F63F53C9732CQ53044360-B6865176-3E99-49E0-A4FC-556E9C10A224Q53102275-7B7DB4B2-FCAA-4620-A3A0-A194C9BD8F25Q53172925-B2DDD1D2-AAB7-4399-85F6-373E5AB4E823Q53298434-8740B08A-3C93-4538-A3ED-505BF69914EEQ54586486-5D84DF4F-434B-425B-A251-35243F6798D7Q57469452-92E74E8E-ABF0-489B-B85A-C906C2B17031Q57587147-CAEAA4F2-A624-4B0B-AB65-2155D2468C3EQ59801838-7D843014-E638-4753-93F2-FBE5B9E953D1Q61447763-35DD2481-6B07-4C52-9552-8E710490ECF4Q61800297-131577B9-EA3E-4C9F-AC9C-A663B6599728Q64007423-E2031400-C170-460E-9460-E77BC429FBA4Q73696690-E0BDE03A-654D-42FC-BCFC-19C0E5C5CC21Q79479050-49702767-447C-482B-85A0-0897A6E57777Q80114123-4E4E56F9-5D74-4DC2-8C5D-03F43FB59B8EQ80966716-B2604B9B-6C7A-4E7A-B63B-353AA6F0380FQ85648701-F841852A-BF27-4E4B-BBDB-69DEDF2BDA79Q86604304-31A99D66-AEA2-48B1-9A70-77CD0E1BC733Q88136355-584E42CE-2DE2-45FF-8784-9685A1F46AC7Q88613460-B6B4EDCC-B758-44EC-A043-DCD2142BD85AQ88932345-56AB49F9-E98A-4738-974A-609C8D5F610AQ90568939-F7799350-07F4-4289-B4D2-916F15DE4E6AQ90658247-2A3E89E5-D5B1-4547-90DA-64C1592C091AQ90989050-FF8AB2D6-37F8-4006-9D6D-258FA0132D8AQ91013728-1194BDE4-4B2C-420C-BC9A-AB72791DB998
P50
description
researcher
@en
wetenschapper
@nl
name
Lucjan S Wyrwicz
@en
Lucjan S Wyrwicz
@nl
Lucjan Wyrwicz
@pl
type
label
Lucjan S Wyrwicz
@en
Lucjan S Wyrwicz
@nl
Lucjan Wyrwicz
@pl
altLabel
Lucjan Stanisław Wyrwicz
@en
Lucjan Stanisław Wyrwicz
@pl
Lucjan Wyrwicz
@en
prefLabel
Lucjan S Wyrwicz
@en
Lucjan S Wyrwicz
@nl
Lucjan Wyrwicz
@pl
P106
P31
P3124
P496
0000-0003-0808-6892